IQV · Full Picture

IQVIA HOLDINGS INC. — the full picture

Trailing window · 2026-05-12 to 2026-08-10

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Capital Return Program · Buybacks & dividendsPriority 69
    1 forward row(s); quote_verified
    IQVIA authorized a $2.00 billion share-repurchase program.
  2. Guidance / Outlook · Guidance & outlookPriority 64
    1 forward row(s); quote_verified
    IQVIA HOLDINGS INC. raised its full-year 2026 revenue guidance to US$17.28–US$17.48 billion.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 59
    quote_verified
    IQVIA reported adjusted EPS of $3.15 and revenue of $4.37 billion for the quarter referenced.
  4. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 34
    1 forward row(s); quote_verified
    Institutional investors collectively hold 89.62% of IQVIA's stock.
  5. Products and Technology · Products & launchesPriority 28
    quote_verified
    A Simply Wall St. article states IQVIA's new alliance with Medera leverages IQVIA's clinical trial infrastructure and Medera's gene therapy work to advance cardiac gene therapy and human-based drug discovery.

Threads by pillar

Revenue & Demand Priority 61 · 2 threads

Capital & Balance Sheet Priority 69 · 1 thread

Strategy & Portfolio Priority 34 · 1 thread

Guidance & Outlook Priority 64 · 1 thread